Topic: Parkinson's disease
Eisai and Biogen's recent Alzheimer's data spark debate; Beijing works to contain a vaccine scandal; BMS and Tsinghua University pen drug discovery pact.
Even if Acorda loses its upcoming appeal on Ampyra's patents, its sales force won’t have to worry, CEO Ron Cohen says.
Intec Pharma is partnering with LTS Lohmann Therapie-Systeme to manufacture its lead drug candidate Accordion Pill carbidopa/levodopa, designed to treat severe symptoms in advanced cases of Parkinson’s disease.
Earlier this month, reports said Acorda could be scouting buyers. And now, rumors are swirling as to who those potential bidders might be.
Pharma marketers aren't limiting their emotional messaging to consumers. These days, they're trying to tap doctors' empathy and compassion, too.
A new disease awareness campaign, sponsored by Acadia Pharmaceuticals, shines a light on the hallucinations and delusions that can affect half of people who have Parkinson’s disease.
Takeda and AZ will team up on Parkinson’s candidate, Samsung Bioepis got nod for a Humira copycat and Daiichi Sankyo said AZ buyout is “not the fact.”
Adamas may be the first company to have won FDA approval for a medication to treat dyskinesia in Parkinson’s patients.
Klick Health's Klick Labs created a programmable device that simulates Parkinson's disease tremors in a bid to create empathy and study its effect on patients.
An add-on Parkinson’s med already available in various countries throughout Europe will soon make its way to U.S. patients.